Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

ABSTRACT: This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

DISEASE(S): Colorectal Cancer,Advanced Solid Tumors,Non-small Cell Lung Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung

PROVIDER: 2343954 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Expression analysis in plasma sample from KRAS G12C–mutant patients monitoring during treatment with KRAS G12C inhibitors

Project description:Follow-up at baseline, 3 days, 6 weeks after the treatment of KRAS G12C mutant patients treated with KRAS G12C inhibitors in blood

2026-02-28 | GSE320266 | GEO

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C

Project description:The discovery of KRAS G12C inactive state inhibitors represents a significant advancement in the field of precision oncology. While inactive state inhibition shows promise in patients, SWII-binding inhibitors targeting both inactive and active states remain an underdeveloped therapeutic modality. Here, we describe the discovery of KRAS G12C dual inhibitors that bind the SWII allosteric site using a chemically differentiated warhead to covalently modify both KRAS G12C inactive and active states. Co-crystal structures reveal that these inhibitors perturb a key water-mediated hydrogen bonding network and trigger allosteric remodeling of the GTP-bound protein surface and Switch I to prevent binding to downstream effectors. Consistent with simultaneous targeting of the active and inactive state, dual inhibitors provide rapid covalent target engagement and suppression of MAPK signaling. However, KRAS G12C dual and inactive state inhibitors demonstrate similar efficacy in cellular and in vivo models despite faster target inhibition afforded by targeting the active state. Furthermore, KRAS G12C dual and inactive state inhibitors show similar cellular efficacy in the presence of growth factors that drive KRAS, wt NRAS and wt HRAS to the active state. These data provide the first detailed account of targeting the active and inactive state of KRAS and highlight the absence of a mechanistic advantage in the context of prolonged KRAS G12C inhibition and efficacy.

2025-11-04 | PXD062227 | Pride

Expression analysis of baseline tissue samples from KRAS G12C–mutant patients and longitudinal blood monitoring during treatment with KRAS G12C inhibitors

Project description:Expression analysis in baseline tissue samples from KRAS G12C mutant patients, follow-up of KRAS mutant patients treated with KRAS G12C inhibitors in blood and analysis of paired biopsies

2026-02-28 | GSE320268 | GEO

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Project description:This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

| 2386408 | ecrin-mdr-crc

RNA-seq of MCF-7 cells treated with GDC-9545 and GNE-858

Project description:We measured gene expression using RNA-sequencing for MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246362 | GEO

ATAC-seq of MCF-7 cells treated with GDC-9545 and GNE-858

Project description:We measured chromatin accessibility using ATAC-sequencing for MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246359 | GEO

RNAseq analysis of GL261 GDC and mNS GSC transcriptome

Project description:We compare the gene expression profile between GL261 glioma differentiated cells (GDC) and mNS Neurospheres glioma stem like cells (GSC).

2017-02-03 | GSE94239 | GEO

MCF-7 RPMI ERa and FOXA1 ChIP-seq in GDC-9545 and GNE-858

Project description:We performed ChIPseq for ER, FOXA1 and H3K27ac on MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246361 | GEO

ChIP-seq of GATA3 in MCF-7 cells treated with GDC-9545 and GNE-858

Project description:We performed ChIPseq for GATA3 on MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246360 | GEO

KRAS G12C inhibition combined with CD47 and immune checkpoint blockage overcomes intrinsic resistance to concomitant KRAS G12C and immune checkpoint inhibitor therapy

Project description:Although KRAS G12C inhibitors have altered the treatment strategy of patients with KRAS G12C mutant lung cancer, their efficacy is insufficient to eliminate tumors. Here, we identified that inhibition of mutant KRAS promotes escape from macrophage phagocytosis by upregulating the expression of ‘don’t eat me’ signal proteins, including CD47. CD47 was induced by the binding of FOXA1 to the super-enhancer of CD47. The addition of an anti-CD47 antibody restored macrophage phagocytosis and phenotype of macrophages.

2025-07-15 | GSE291687 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data